Dr. Michel Roberge is a Professor in the Department of Biochemistry and Molecular Biology at the University of British Columbia. He obtained his PhD from the University of Heidelberg, Germany, and carried out postdoctoral work at the University of California, Davis, USA and at the Swiss Institute for Cancer Research, Epalinges, Switzerland. He has been at UBC since 1991. He has trained 17 graduate students, 10 postdoctoral fellows and over 60 undergraduate students. He was a co-founder of the Centre for Drug Research and Development, he has served as CDRD Scientific Director and Chair of the Centre’s Drug Screening Division. He specializes in chemical biology and drug discovery. He is a leader in the development of cell-based and high content screening assays. His work has led to the identification of small molecules affecting diverse cellular processes and enzymes such as autophagy, cancer cell invasion, cell cycle checkpoints, mitotic progression, mitotic slippage, mTOR signaling, protein phosphatases, v-ATPase and indoleamine dioxygenase, for the treatment of cancer. His work is currently focused on the discovery and development of bioactive small molecules for the treatment of rare genetic diseases.
